FrancophonIA/ELRC3.0 huggingface dataset:
Italian: Secondo alcuni studi epidemiologici le fratture sottotrocanteriche e diafisarie del femore possono essere costituite da normali fratture osteoporotiche (Abrahamsen et al., 20096, Abrahamsen, 20107, Vestergaard et al., 20108), mentre secondo altri l'uso di bisfosfonati a lungo termine può aumentare il rischio del loro verificarsi (Park-Wyllie et al., 20119, Wang e Bhattacharyya, 201110).
Latvian: Lai gan daži epidemioloģiskie pētījumi ļauj spriest, ka subtrohanterie un augšstilba kaula kakliņa lūzumi varētu būt parasti osteoporozes lūzumi (Abrahamsen et al, 20096, Abrahamsen, 20107, Vestergaard et al, 20108), citi pētījumi liek domāt, ka ilgstoša bifosfonātu lietošana var palielināt subtrohantero un augšstilba kaula kakliņa lūzumu risku (Park-Wyllie et al, 20119, Wang & Bhattacharyya, 201110).
Italian: Benché gli studi preclinici abbiano fornito scarse informazioni sul rischio di fratture atipiche con i bisfosfonati, alcuni hanno dimostrato che la soppressione del turnover osseo indotta dai bisfosfonati potrebbe aumentare l'accumulo di microdanni, nonché quello di prodotti finali della glicazione avanzata con conseguenti cambiamenti nelle proprietà biomeccaniche delle ossa (Brennan et al., 2011, Hofstaetter et al., 2010, Mashiba et al., 2000, O'Neal et al., Tang et al., 20091).
Latvian: Lai gan pirmsklīniskie pētījumi sniedza ierobežotu informāciju par patoloģisko lūzumu risku saistībā ar bifosfonātiem, dažos no šiem pētījumiem bija redzams, ka bifosfonātu izraisītā kaulaudu reģenerācijas ierobežošana var palielināt mikroskopisku bojājumu uzkrāšanos un progresējošu glikācijas galaproduktu uzkrāšanos, kas izraisa kaula biomehānisko īpašību izmaiņas (Brennan et al, 2011, Hofstaetter et al, 2010, Mashiba et al, 2000, O'Neal et al, Tang et al, 20091).
Italian: • aggiunta della frattura atipica del femore alla sezione 4.8 (Effetti indesiderati) del riassunto delle caratteristiche del prodotto, seguita da una dichiarazione attestante che questo effetto avverso costituisce una caratteristica di classe di tutti i bisfosfonati.
Latvian: • ZA 4.8. apakšpunktā (Nevēlamās blakusparādības) pievienot patoloģisku augšstilba kaula lūzumu un papildināt to ar paziņojumu, ka šī nevēlamā blakusparādība ir raksturīga visai bifosfonātu grupai.
Italian: J Bone Miner Res 25 (Suppl 1) 2010; disponibile su http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=223582c5-f5bb-4d66-bd16
Latvian: J Bone Miner Res 25 (Suppl 1) 2010; Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=223582c5-f5bb-4d66-bd16d073267b2a47.
Italian: Anche trattamenti concomitanti con altri medicinali antiriassorbitivi, come la terapia ormonale sostitutiva e la terapia con raloxifene, sono stati indicati come possibili fattori di rischio.
Latvian: Kā iespējami riska faktori ir ierosināta arī vienlaicīga ārstēšana ar citām resorbciju kavējošām zālēm, piemēram, ar hormonu aizstājterapiju un raloksifēnu.
Italian: Alcuni studi caso-controllo hanno segnalato un'associazione significativa tra i pattern di fratture atipiche del femore e l'uso di bisfosfonati (Lenart et al., 200911, Isaacs et al., 201012).
Latvian: Gadījumu kontroles pētījumos ir ziņots par būtisku saistību starp patoloģisku augšstilba kaula lūzumu modeli un bifosfonātu lietošanu (Lenart et al, 200911, Isaacs et al, 201012).
Italian: I bisfosfonati sono medicinali usati per trattare e prevenire disturbi ossei come l'ipercalcemia, per prevenire problemi ossei in pazienti affetti da cancro, nonché per curare l'osteoporosi e la malattia di Paget.
Latvian: Bifosfonāti ir zāles, kas tiek izmantotas kaulu traucējumu, tostarp hiperkalcēmijas, ārstēšanai un kaulu problēmu profilaksei pacientiem ar vēzi, osteoporozes un Pedžeta slimības ārstēšanai.
Italian: Si ritiene che l'uso di bisfosfonati a lungo termine rappresenti il principale fattore di rischio delle fratture atipiche del femore.
Latvian: Ilgstoša bifosfonātu lietošana tiek uzskatīta par patoloģisku augšstilba kaula lūzumu galveno riska faktoru.
Italian: (Avvertenze speciali e precauzioni di impiego) relativa a tale rischio, alle principali caratteristiche di queste fratture e all'eventuale necessità di interruzione del trattamento qualora sussista il sospetto di una frattura;
Latvian: • ZA 4.4. apakšpunktā (Īpaši brīdinājumi un piesardzība lietošanā) pievienot brīdinājumu, atspoguļot šo risku, šo lūzumu galvenās īpašības un iespējamo nepieciešamību pārtraukt ārstēšanu, ja radušās aizdomas par lūzumu.
Italian: J Orthop Res 2009; 27: 1288-1292 3 Shane E et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.
Latvian: J Orthop Res 2009; 27: 1288-1292 3 Shane E et al Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American
Italian: J Bone Miner Res 25 (Suppl 1) 2010; disponibile su http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=05caf316-b73e-47b8-a011-bf0766b062c0.
Latvian: Available at http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=05caf316-b73e-47b8-a011bf0766b062c0.
Italian: Oltre all'osteoporosi, le principali condizioni di comorbilità individuate in pazienti con fratture atipiche del femore sono state malattia polmonare cronica ostruttiva o asma, artrite reumatoide e diabete.
Latvian: Pacientiem ar patoloģisku augšstilba kaula lūzumu kā visbiežāk sastopamie patoloģiskie traucējumi bez osteoporozes ir konstatēta hroniska obstruktīva plaušu slimība vai astma, reimatoīdais artrīts un diabēts.
Italian: Data di accesso: 5 aprile 2011 6 Abrahamsen B et al. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.
Latvian: 6 Abrahamsen B et al Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.
Italian: Il potenziale rischio di fratture atipiche in zone corporee diverse da quella del femore sarà tenuto sotto controllo.
Latvian: Potenciālais patoloģisko lūzumu risks vietās, kas nav augšstilba kauls, tiks pastāvīgi izvērtētas.
Italian: J Bone Miner Res 2010; 25: 2267-2294
Latvian: Society for Bone and Mineral Research. J Bone Miner Res 2010; 25: 2267-2294
Italian: Dopo l'esame condotto dal gruppo di lavoro farmacovigilanza nel 2008, il numero di segnalazioni postimmissione in commercio relative a possibili fratture atipiche del femore associate a bisfosfonati è aumentato.
Latvian: Kopš PhVWP pārskatīšanas 2008. gadā ir palielinājies pēcreģistrācijas ziņojumu skaits par patoloģisko augšstilba kaula lūzumu iespējamo saistību ar bifosfonātiem.
Italian: Il comitato ha concluso inoltre che nella sezione 4.2 delle informazioni del prodotto per i bisfosfonati autorizzati per la cura dell'osteoporosi devono essere aggiunte informazioni sulla necessità di valutare periodicamente l'esigenza di proseguire il trattamento con i bisfosfonati, in particolare dopo cinque anni di cura, a seconda dei singoli pazienti.
Latvian: Turklāt, ņemot vērā pierādījumu trūkumu attiecībā uz optimālo bifosfonātu lietošanas ilgumu osteoporozes ārstēšanā un pieņemot, ka ārstēšanas ilgums ir patoloģisku augšstilba kaula lūzumu riska faktors, CHMP arī ieteica osteoporozes ārstēšanai apstiprināto bifosfonātu zāļu apraksta 4.2. apakšpunktā pievienot informāciju par nepieciešamību regulāri izvērtēt nepieciešamību turpināt ārstēšanu, lietojot bifosfonātus, jo īpaši pēc piecu gadu ārstēšanas perioda, katram pacientam atsevišķi.
Italian: Dopo un esame condotto dal gruppo di lavoro farmacovigilanza nel 2008, si è giunti alla conclusione di aggiungere un'avvertenza sulle fratture atipiche da stress della diafisi prossimale del femore alle informazioni del prodotto per i medicinali contenenti acido alendronico in tutta Europa.
Latvian: Pēc farmakoloģiskās uzraudzības darba grupas (PhVWP) pārskata 2008. gadā tika secināts, ka alendronskābi saturošām zālēm visā Eiropā zāļu aprakstam ir jāpievieno brīdinājums par augšstilba kaula proksimālā kakliņa patoloģiskiem stresa lūzumiem.
Italian: Data di accesso: 15 febbraio 2011 14 Schilcher J et al. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonates.
Latvian: 14 Schilcher J et al Incidence of stress fractures of the femoral shaft in women treated with bisphosphonates.
Italian: Tuttavia, sono stati ipotizzati vari meccanismi possibili di fratture atipiche associate all'uso di bisfosfonati.
Latvian: Tomēr saistībā ar bifosfonātu lietošanu ir ierosināti vairāki iespējamie patoloģisko lūzumu mehānismi.
Italian: 2007 to 2009.
Latvian: Accessed 5 April 2011
Italian: La mancanza di segnalazioni sui restanti bisfosfonati, costituiti da acido clodronico, acido neridronico e acido tiludronico, può essere attribuita al minore utilizzo di questi medicinali rispetto ad altri bisfosfonati.
Latvian: Ziņojumu trūkums par atlikušajiem bifosfonātiem - klodronskābi, neridronskābi un tiludronskābi - var būt saistīts ar šo zāļu mazo lietojumu, salīdzinot ar citiem bifosfonātiem, un tāpēc nevar izslēgt to iespējamo saistību.
Italian: 2 Burr DB et al. Effects of one to three years treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk.
Latvian: Osteoporosis Int 2009; 20: 887-894 2 Burr DB et al Effects of one to three years treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk.
Italian: Definizione di frattura atipica del femore
Latvian: Augšstilba kaula patoloģiska lūzuma definīcija
Italian: Segnalazioni post-immissione in commercio
Latvian: Pēcreģistrācijas ziņojumi
Italian: I glucocorticoidi e l'inibitore della pompa protonica (PPI) sono stati identificati quali possibili e importanti fattori di rischio di fratture atipiche del femore.
Latvian: Patoloģiskam augšstilba kaula lūzumam kā iespējamie nozīmīga riska faktori ir noteikti glikokortikoīdi un protonu sūkņa inhibitors (PSI).
Italian: È stato segnalato un certo numero di possibili fattori di rischio di fratture atipiche del femore legate all'uso di bisfosfonati.
Latvian: Saistībā ar bifosfonātu lietošanu patoloģiskajiem augšstilba kaula lūzumiem ir ierosināti vairāki iespējamie riska faktori.
Italian: Geriatrics 2006; 61: 31-33 5 Nitche J et al. Subtrochanteric femoral stress fractures in patients on chronic bisphosphonate therapy: a case series.
Latvian: 5 Nitche J et al Subtrochanteric femoral stress fractures in patients on chronic bisphosphonate therapy: a case series.
Italian: J Bone Miner Res 2011; DOI 10.1002/jbmr.233
Latvian: J Bone Miner Res 2009; 24: 1095-1102
Italian: Per tutti i bisfosfonati
Latvian: Attiecībā uz visiem bifosfonātiem
Italian: ALLEGATO IV Condizioni dell'autorizzazione all'immissione in commercio
Latvian: IV pielikums Reģistrācijas apliecības nosacījumi
Italian: La comunicazione deve basarsi sul "documento di messaggi chiave di comunicazione" approvato dal CHMP e accluso alla relazione di valutazione.
Latvian: Šim paziņojumam ir jābūt pamatotam ar „key communication messages document" (galveno saziņas paziņojumu dokumentu), ko pieņēmusi CHMP un kas pievienota novērtējuma ziņojuma pielikumā.
Italian: Entro due mesi dalla decisione della Commissione, detti titolari devono rivolgersi alle autorità nazionali competenti per stabilire i termini di presentazione dei piani di gestione del rischio; le autorità nazionali competenti assicurino che gli operatori siano informati delle misure concordate dal CHMP per ridurre al minimo il rischio di fratture atipiche del femore.
Latvian: Divu mēnešu laikā pēc Komisijas lēmuma pieņemšanas RAĪ sadarbībā ar valstu kompetentajām iestādēm ir jāvienojas par laika grafikiem attiecībā uz riska pārvaldības plānu iesniegšanu.
Italian: Le autorità nazionali competenti, possibilmente coordinate dallo Stato membro di riferimento, hanno il compito di assicurare che: i titolari dell'autorizzazione all'immissione in commercio presentino/aggiornino i piani di gestione del rischio per considerare le "fratture atipiche del femore" come un rischio potenziale.
Latvian: RAĪ ir jāiesniedz/jāatjaunina riska pārvaldības plāni, kā potenciālu risku norādot „patoloģiskus augšstilba kaula lūzumus".
Italian: Av. Associação Comercial e Industrial de Gondomar, 330 - Zona Industrial da Portelinha
Latvian: Associação Comercial e Industrial de Gondomar, 330 - Zona Industrial da Portelinha
Italian: Polígono 8 - Parcela 20.
Latvian: Polígono 8 - Parcela 20. Crta.
Italian: Pol. Industrial Alcobendas 28108 Alcobendas
Latvian: Industrial Alcobendas 28108 Alcobendas
Italian: PT - Portogallo Premium PharmaSociedade Técnico
Latvian: PT - Portugāle Premium PharmaSociedade Técnico
Italian: PT - Portogallo Mepha - Investigação, Desenvolvimento e
Latvian: PT - Portugāle Mepha - Investigação, Desenvolvimento e
Italian: ALLEGATO I Lista dei nomi, delle forme farmaceutiche, delle potenze di prodotti medicinali, modo e via di somministrazione, titolari dell'autorizzazione in commercio negli stati membri.
Latvian: ZĀĻU NOSAUKUMI, ZĀĻU FORMAS, STIPRUMSI, LIETOŠANAS VEIDI, REĢISTRĀCIJAS APLIECĪBU ĪPAŠNIEKSI DALĪBVALSTĪS
Italian: BG - Bulgaria Tchaikapharma High Quality Medicines, 1, G.M.
Latvian: BG - Bulgārija Tchaikapharma High Quality Medicines, 1, G.M.
Italian: Ingers Industrial Soluziones, s.r.o.
Latvian: Ingers Industrial Solutions, s.r.o.
Italian: Av. José Malhoa - Edifício Malhoa Plaza nº 2, pisoescritório 2.2
Latvian: José Malhoa - Edifício Malhoa Plaza nº 2, pisoescritório 2.2
Italian: NO - Norvegia Meda, postboks 194, 1371 Asker Norawy
Latvian: NO - Norvēģija Meda, postboks 194, 1371 Asker Norawy
Italian: 103, blvd Al. Stamboliyski Office Building Sofia Tower Level 8, 1303 Sofia Bulgaria
Latvian: 103, blvd Al. Stamboliyski Office Building Sofia Tower Level 8, 1303 Sofia
Italian: PT - Portogallo Ratiopharm - Comércio e Indústria de Produtos
Latvian: PT - Portugāle Ratiopharm - Comércio e Indústria de Produtos
Italian: PT - Portogallo Jaba Recordati, S. A. Lagoas Park, Edificio 5, Torre C, Piso 3
Latvian: PT - Portugāle Jaba Recordati, S. A. Lagoas Park, Edificio 5, Torre C, Piso 3
Italian: Ind. Malpica Calle C, Nº 4 50016 Zaragoza
Latvian: Malpica Calle C, Nº 4 50016 Zaragoza
Italian: PT - Portogallo ToLife - Produtos Farmacêuticos, S.A.´ Avenida do Forte, 3Edificio Suécia III, Piso 1
Latvian: PT - Portugāle ToLife - Produtos Farmacêuticos, S.A.´ Avenida do Forte, 3Edificio Suécia III, Piso 1
Italian: 2100 Gödöllő, Repülőtéri út
Latvian: Teva Magyarország Zrt. 2100 Gödöllő, Repülőtéri út
Italian: Av. D. João II, 10 EsqºTorre Fernão de Magalhães 1998-025 Lisboa, Portugal
Latvian: D. João II, 10 EsqºTorre Fernão de Magalhães 1998-025 Lisboa, Portugal
Italian: Poligono Industrial Colon II.
Latvian: Venus, 72. Poligono Industrial Colon II.
Italian: SPA - SOCIETA' PRODOTTI ANTIBIOTICI SpA Via Biella, 8
Latvian: PRODOTTI ANTIBIOTICI SpA Via Biella, 8
Italian: TRABECAN Duo TEVA compresseta és lágy kapszula
Latvian: TRABECAN Duo TEVA tabletta és lágy kapszula
Italian: PT - Portogallo Optimal Regulatory Soluziones, S.L. Via
Latvian: PT - Portugāle Optimal Regulatory Solutions, S.L.
Italian: Hungary ( The company is the member of TEVA Group Teva Magyarország zRt,1134budapest, Róbert Károly krt.59))
Latvian: 1036 Budapest Hungary ( The company is the member of TEVA Group Teva Magyarország zRt,1134budapest, Róbert Károly krt.59))
Italian: TH. PETALA 41
Latvian: PETALA 41
Italian: PT - Portogallo ISUS - Produtos Farmacêuticos e
Latvian: PT - Portugāle ISUS - Produtos Farmacêuticos e
Italian: Str. Izvor, nr 80, etajele 611, sector 5 Bucharest, Romania
Latvian: Izvor, nr 80, etajele 611, sector 5 Bucharest,
Italian: Ks. J. Poniatowskiego st. 5 05-825 Grodzisk Mazowiecki, Poland
Latvian: J. Poniatowskiego st. 5 05-825 Grodzisk Mazowiecki, Poland
Italian: LABORATORIOS COMBIX, S.L.San Rafael, 3.
Latvian: LABORATORIOS COMBIX, S.L.San Rafael, 3. Pol.
Italian: 2051 Biatorbágy
Latvian: 2051 Biatorbágy Hungary
Italian: LV - Latvia
Latvian: LV - Latvija
Italian: NO - Norvegia Teva Sweden AB, Box 1070, 25110 Helsingborg, Sweden
Latvian: NO - Norvēģija Teva Sweden AB, Box 1070, 25110 Helsingborg, Sweden
Italian: Off.: Suite No. 10 & 11 Sage House
Latvian: 10 & 11 Sage House
Italian: HU - Ungheria Sanofi-aventis zrt.
Latvian: HU - Ungārija sanofi-aventis zrt.
Italian: UK - Regno Unito Sanofi-Synthelabo Limited, One Onslow Street,
Latvian: UK - Lielbritānija Sanofi-Synthelabo Limited, One Onslow Street,
Italian: LV - Latvia sanofi-aventis Latvia SIA, Kr.Valdemara iela 33-8, Riga LV 1010, Latvia
Latvian: LV - Latvija sanofi-aventis Latvia SIA, Kr.Valdemara iela 33-8, Riga LV 1010, Latvia
Italian: UK - Regno Unito Ranbaxy (UK) Limited, 95 Park Lane, Mayfair.
Latvian: UK - Lielbritānija Ranbaxy (UK) Limited, 95 Park Lane, Mayfair.
Italian: NO - Norvegia Sandoz A/S, Edvard Thomsens Vej 14, DK-2300
Latvian: NO - Norvēģija Sandoz A/S, Edvard Thomsens Vej 14, DK-2300
Italian: UK - Regno Unito Caduceus Pharma Limited, 6th floor, 94 Wigmore
Latvian: UK - Lielbritānija Caduceus Pharma Limited, 6th floor, 94 Wigmore
Italian: Al. Jana Pawła II 23
Latvian: Jana Pawła II 23
Italian: Al. Jana Pawła II 80
Latvian: Jana Pawła II 80
Italian: PT - Portogallo Dr. Reddy's Laboratories (UK) Ltd.
Latvian: PT - Portugāle Dr. Reddy's Laboratories (UK) Ltd.
Italian: D-61381 Friedrichsdorf
Latvian: 36b D-61381 Friedrichsdorf
Italian: UK - Regno Unito Apsala Limited, bayview House, 49 Northstrand Road,Dublin 3, Ireland
Latvian: UK - Lielbritānija Apsala Limited, bayview House, 49 Northstrand Road,Dublin 3, Ireland
Italian: HU - Ungheria Medac GmbH Fehlandstrasse 3.
Latvian: HU - Ungārija Medac GmbH Fehlandstrasse 3.
Italian: Südwestpark 50
Latvian: Generica KG Südwestpark 50
Italian: NL - Olanda ratiopharm Nederland bv Florapark 4
Latvian: NL - Nīderlande ratiopharm Nederland bv Florapark 4
Italian: Via Morolense, 87 - 03010 Ferentino
Latvian: Via Morolense, 87 - 03010
Italian: RO - Romania BAYER SCHERING PHARMA OY,
Latvian: RO - Rumānija BAYER SCHERING PHARMA OY,
Italian: PT - Portogallo Arrow ApS Hovedgaden 41, 2, 2970 Horsholm
Latvian: PT - Portugāle Arrow ApS Hovedgaden 41, 2, 2970 Horsholm
Italian: SK - Slovacchia medac GmbH Theaterstraße 6
Latvian: SK - Slovākija medac GmbH Theaterstraße 6
Italian: UK - Regno Unito Ratiopharm GmbH, 5 Jackson Close, Grove Road, Cosham, Portsmouth, Hampshire, PO6 1UP
Latvian: UK - Lielbritānija Ratiopharm GmbH, 5 Jackson Close, Grove Road, Cosham, Portsmouth, Hampshire, PO6 1UP
Italian: FI - Finlandia sanofi-Aventis Oy, Huopalahdentie 24, PL 22, 00350 Helsinki, Finland
Latvian: FI - Somija sanofi-Aventis Oy, Huopalahdentie 24, PL 22, 00350 Helsinki, Finland
Italian: STADA Hemofarm SRL Zugrav Nedelcu nr.3, Timişoara, Romania
Latvian: RO - Rumānija STADA Hemofarm SRL Zugrav Nedelcu nr.3, Timişoara, Romania
Italian: NO - Norvegia Merck Sharp and Dohme B.V., Postbus 581,
Latvian: NO - Norvēģija Merck Sharp and Dohme B.V., Postbus 581,
Italian: UK - Regno Unito Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7
Latvian: UK - Lielbritānija Roche Products Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL7
Italian: UK - Regno Unito Dr Reddy's Laboratories (UK) Limited, 6 Riverview Road, Beverley, East
Latvian: UK - Lielbritānija Dr Reddy's Laboratories (UK) Limited, 6 Riverview Road, Beverley, East
Italian: UK - Regno Unito Pliva Pharma Limited, Vision House, Bedford Road,
Latvian: UK - Lielbritānija Pliva Pharma Limited, Vision House, Bedford Road,
Italian: HU - Ungheria Ozone Laboratories BV 2 Martinus Nijhofflaan 2624 ES Delft
Latvian: Ozone Laboratories BV 2 Martinus Nijhofflaan 2624 ES Delft Holland
Italian: SK - Slovacchia Actavis Group PTC ehf Dalshraun 1
Latvian: SK - Slovākija Actavis Group PTC ehf Dalshraun 1
Italian: Str. Av. Petre Creţu, nr.74, Sector 1, Bucureşti, Romania
Latvian: Petre Creţu, nr.74, Sector 1, Bucureşti, Romania
Italian: Ind. Los Mochos.
Latvian: Los Mochos.
Italian: HU - Ungheria Sandoz Hungária Kft., 1114 Budapest, Bartók Béla út 43-47.
Latvian: Sandoz Hungária Kft., 1114 Budapest, Bartók Béla út 43-47.
Italian: UK - Regno Unito Sandoz Limited, 37 Woolmer Way, Bordon, Hampshire GU35 9QE
Latvian: UK - Lielbritānija Sandoz Limited, 37 Woolmer Way, Bordon, Hampshire GU35 9QE
Italian: Novartis s.r.o., U nákladového nádraží 3265/10, 130 00 PrahaStrašnice (Nagano III.
Latvian: Novartis s.r.o., U nákladového nádraží 3265/10, 130 00 PrahaStrašnice (Nagano III.), Czech Republic
Italian: UK - Regno Unito Teva UK Limited, Brampton Road, Hampden Park,
Latvian: UK - Lielbritānija Teva UK Limited, Brampton Road, Hampden Park,
Italian: Galex, d.d., Tišinska ulica 29g, Murska Sobota,
Latvian: Galex, d.d., Tišinska ulica 29g, Murska Sobota, Slovenia
Italian: DK - Danimarca Bayer AB, Postbox 606, Gustav III:s Boulevard 56, SE-16926 Solna
Latvian: Bayer AB, Postbox 606, Gustav III:s Boulevard 56, SE-16926 Solna
Italian: UK - Regno Unito Strandhaven Limited, 600 High Road, Seven Kings, Ilford, Essex IG3 8BS,
Latvian: UK - Lielbritānija Strandhaven Limited, 600 High Road, Seven Kings, Ilford, Essex IG3 8BS,
Italian: UK - Regno Unito Wockhardt UK Limited, Ash Road North, Wrexham
Latvian: UK - Lielbritānija Wockhardt UK Limited, Ash Road North, Wrexham
Italian: HELP S.A. Pharmaceuticals 10, Valaoritou Str.
Latvian: Pharmaceuticals 10, Valaoritou Str.
Italian: DE - Germania esparma GmbH Seepark 7
Latvian: DE - Vācija esparma GmbH Seepark 7
Italian: UK - Regno Unito Bayer Plc, bayer House, Strawberry Hill, Newbury, Berkshire, RG14 1JA, UK
Latvian: UK - Lielbritānija Bayer Plc, bayer House, Strawberry Hill, Newbury, Berkshire, RG14 1JA, UK
Italian: ET - Estonia
Latvian: ET - Igaunija
Italian: PT - Portogallo Mer Medicamentos, Lda.
Latvian: PT - Portugāle Mer Medicamentos, Lda.
Italian: UK - Regno Unito Laboratorios Davur S.L., Calle Teide 4.
Latvian: UK - Lielbritānija Laboratorios Davur S.L., Calle Teide 4. Parque
Italian: Ostac, concentrato per soluzione per infusione 30 mg/ml
Latvian: Ostac, concentration for solution for infusion 30 mg/ml
Italian: Spafield, Cork Road, Cashel, Co. Tipperary
Latvian: Spafield, Cork Road, Cashel, Co.
Italian: Cosméticos, S.A. Rua António Quadros, 9GEscritório 3 1600-875
Latvian: Rua António Quadros, 9GEscritório 3 1600-875
Italian: C.F. Tietgens Boulevard 40 DK-5220 Odense SØ Denmark
Latvian: Tietgens Boulevard 40 DK-5220 Odense SØ Denmark
Italian: Calcisedron-D Trio filmcompresseta
Latvian: Calcisedron-D Trio filmtabletta
Italian: CZ - Repubblica Ceca
Latvian: CZ - Čehijas Republika
Italian: Sanofi-Aventis Bulgaria EOOD
Latvian: BG - Bulgārija Sanofi-Aventis Bulgaria EOOD
Italian: Edifício Atlas II, Av. José Gomes Ferreira, N.º 11 - 3º, Sala 31,
Latvian: José Gomes Ferreira, N.º 11 - 3º, Sala 31,
Italian: SK - Slovacchia Sandoz Pharmaceuticals d.d.
Latvian: SK - Slovākija Sandoz Pharmaceuticals d.d.
Italian: DK - Danimarca Sanofi-Aventis Denmark A/S, Slotsmarken 13, DK3970 Hørsholm, Denmark
Latvian: Sanofi-Aventis Denmark A/S, Slotsmarken 13, DK3970 Hørsholm, Denmark
Italian: PT - Portogallo Apotex Europe, B.V.
Latvian: PT - Portugāle Apotex Europe, B.V.
Italian: NO - Norvegia Sanofi-aventis, Strandveien 15, 1366 Lysaker Norway
Latvian: NO - Norvēģija Sanofi-aventis, Strandveien 15, 1366 Lysaker Norway
Italian: SK - Slovacchia Bentley Pharmaceuticals Ireland Limited
Latvian: SK - Slovākija Bentley Pharmaceuticals Ireland Limited
Italian: Cosméticos, S.A. Rua António Quadros, 9GEscritório 3,
Latvian: Rua António Quadros, 9GEscritório 3,
Italian: SK - Slovacchia Zaklad Farmaceutyczny Adamed Pharma SA
Latvian: SK - Slovākija Zaklad Farmaceutyczny Adamed Pharma SA
Italian: NO - Norvegia Bayer AB Box 606
Latvian: NO - Norvēģija Bayer AB Box 606
Italian: UK - Regno Unito Prostrakan Limited, 3 Galabank Business Park, Queen Street, Galashiels, TD1 1QH, United Kingdom
Latvian: UK - Lielbritānija Prostrakan Limited, 3 Galabank Business Park, Queen Street, Galashiels, TD1 1QH, United Kingdom
Italian: 2012 HK Haarlem Netherlands
Latvian: 2012 HK Haarlem
Italian: PT - Portogallo Aurobindo Pharma (Portugal), Unipessoal Lda.
Latvian: PT - Portugāle Aurobindo Pharma (Portugal), Unipessoal Lda.